ABSTRACT
Introduction Supraglottic airway devices represent a less invasive method of airway management than tracheal intubation during general anaesthesia. Their continued development is focused mainly on improvements in the insertion success rate and minimalization of perioperative and postoperative complications. The i-gel Plus is a novel, anatomically preshaped supraglottic airway device which achieves a perilaryngeal seal due to a non-inflatable cuff made of a soft thermoplastic elastomer. The purpose of this trial is to assess the success rate of the i-gel Plus use during elective procedures under general anaesthesia, its intraoperative performance, and the degree of postoperative complications.
Methods and analysis This is a multicenter, prospective, interventional cohort study. The enrolment will take place in seven centers in four European countries. We plan to enrol 2000 adult patients in total, who are scheduled for elective surgery under general anaesthesia, and with an indication for use of a supraglottic airway device for management of their airway. The study is projected to run over a period of 18 months. The primary outcome of the study is the total success rate of the i-gel Plus insertion in terms of successful ventilation and oxygenation through the device. Secondary outcomes include perioperative parameters, such as insertion time, seal/leak pressures, number of insertion attempts, and postoperative adverse events and complications. Postoperative follow-up will be performed at 1 hour, 24 hours in all patients, and for selected patients at 3 and 6 months.
Ethics and dissemination The trial has received the following ethical approvals: General University Hospital Prague, University Hospital Olomouc, University Military Hospital Prague, University Hospital Barcelona, University Hospital Lodz, Antrim Area Hospital, Craigavon Area Hospital, Office for Research Ethics Committees Northern Ireland. The results will be published in peer-reviewed journals and presented at relevant anaesthesia conferences.
Trial registration number ISRCTN86233693
Strengths and limitations of this study
- The study will provide the first data about the use of the novel supraglottic airway device, the i-gel Plus for maintaining ventilation and oxygenation during anaesthesia.
- Broad inclusion criteria and the multicenter, multinational design of the study will allow study of a wide spectrum of populations of different age, gender and ethnicity and thus provide more generalisable results.
- Patients showing significant postoperative adverse effects will be followed up for up to 6 months which will provide information about the long-term complication rates of the device.
- The main limitation of the study is that the device will be trialled only in selected elective procedures and not as a rescue device or in difficult airway management scenarios.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ISRCTN86233693
Funding Statement
This work is supported by the Czech Ministry of Health, grant no. MZCZ-DRO-VFN64165
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee of the General University Hospital in Prague (study sponsor) in November 2019 (No. 1952/19 S-IV, received 14/11/2019, dr. J. Sedivy, Chair). The Czech Ministry of Health will act as a sponsor and partial founder via General University Hospital in Prague (grant number MZCZ-DRO-VFN64165). Following this initial approval, the ethical approvals from other centres were obtained: University Hospital Olomouc (No. 18/20, received 10/02/2020, Dr. J. Buresova, chair), University Hospital in Lodz (No. RNN/61/20/KE, received 03/03/2020, Prof. J. Drzewoski, chair), University Hospital in Barcelona (No. HCB 2020/0771, received 08/09/2020, Dr. A.L. Arellano Andrino, secretary), Northern HSC Trust for Antrim Area Hospital in Antrim (No. NT20-278410-10, received 10/12/2020, Dr. M. Rooney, Trust Director of Research and Development), Southern HSC Trust for Craigavon Area Hospital (No. ST2021/31, received 22/04/2021, Dr. P. Sharpe, Trust Director of Research and Development), Office for Research and Ethical Committee Northern Ireland (ORECNI) (REC 20/NI/0140, received 27/11/2020, Prof. P. Murphy, HSC REC B Chair), University Military Hospital in Prague (No. 108/15-104/2020, received 21/12/2020, Prof. J. Plas, chair).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Contact details: O. Klementova (olga.klementova{at}fnol.cz), T.K. Bhoday (tkbhoday{at}gmail.com), J. Werner (jakub.werner{at}vfn.cz), A.M. Lopez (analopez{at}clinica.cat), W. Donaldson (william.donaldson{at}northerntrust.hscni.net), E. Lichnovsky (erik.lichnovsky{at}southerntrust.hscni.net), T. Gaszynski (tomasz.gaszynski{at}umed.lodz.pl), T. Henlin (tomas.henlin{at}uvn.cz), J. Bruthans (jan.bruthans{at}vfn.cz), J. Ulrichova (jitka.ulrichova{at}vfn.cz), M. Lukes (martin.lukes{at}vfn.cz), J. Blaha (jan.blaha{at}vfn.cz), M. Kral (michal.kral2{at}fnol.cz, L. Gomez (lgomez2{at}clinic.cat), R. Berge (rberge{at}clinic.cat), J. Holland (jonathan.holland{at}northerntrust.hscni.net), F. McAleavey (francis.mcaleavey{at}northerntrust.hscni.net), S. Arava (shiva.arava{at}southerntrust.hscni.net), L. Merjava Skripecka (lubica.merjavaskripecka{at}southerntrust.hscni.net), S. Sobczyk (sebastian.sobczyk{at}umed.lodz.pl), T. Tyll (tomas.tyll{at}uvn.cz), P. Michalek (pavel.michalek{at}vfn.cz)
Data Availability
After completion of the trial, the data will be shared using a public depository (https://data.mendeley.com).
